Nasdaq:FDMT
4D Molecular Therapeutics, Inc.
A clinical-stage biopharmaceutical firm developing small molecule therapeutics for oncology and immunology indications.
Key Metrics
Investment Thesis
Bull Case
Investors may consider FDMT based on its robust liquidity position, holding over $324M in cash and securities which provides ample runway for clinical progression without immediate dilution. The proprietary small molecule platform offers a differentiated approach to oncology targets that could yield high-value approvals if successful. Early-stage biotech stocks with large cash reserves often present asymmetric upside opportunities if key clinical milestones are met.
Bear Case
The stock is vulnerable due to deteriorating profitability and zero revenue in the most recent year, signaling potential strategic or commercial setbacks. The rapid expansion of operating losses and a growing retained earnings deficit suggests the company cannot sustain its current burn rate indefinitely without external funding. Investors should avoid this position if they lack tolerance for the high probability of clinical trial failure common in late-stage biotechnology development.
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. (FDMT) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs for serious unmet medical needs in oncology and immunology. The company primarily operates through its proprietary platform to identify new therapeutic targets, with recent financials showing minimal revenue generation as it allocates resources toward advancing its pipeline candidates through clinical trials. With a strong cash position relative to liabilities, the firm maintains liquidity while navigating the high-risk development phase typical of early-stage biotechnology.
Analysis
Management Discussion
Recent financial performance indicates a challenging trajectory with net profit widening into a deficit of $160.9M in 2024, up from losses of $107.5M and $100.8M in previous years. While the company holds substantial cash and marketable securities totaling over $324M, operating expenses have surged to nearly $188M, outpacing any minimal revenue generation of $37k. The shift from positive cash flow in financing activities to a net decrease in cash highlights the intense capital consumption required to advance its drug development pipeline.
Industry Overview
The biopharmaceutical industry is characterized by high R&D expenditures, long development cycles, and significant regulatory hurdles before products can reach market. Companies like FDMT compete against large pharmaceutical giants and other innovative biotechs for funding and talent in the oncology sector. Success in this industry requires securing multiple clinical trial approvals to navigate a crowded pipeline while managing substantial cash burn.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $3.1M | $20.7M | $37.0K |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $3.1M | $20.7M | $37.0K |
| Operating Expenses | $113.2M | $133.6M | $187.9M |
| Operating Income | $-110.0M | $-112.9M | $-187.8M |
| G&A | $32.9M | $36.5M | $46.6M |
| Stock-Based Comp | $17.1M | $19.7M | $26.1M |
| D&A | $2.4M | $4.2M | $4.7M |
| Depreciation | $2.4M | $4.4M | $4.8M |
| Other OpEx | $80.3M | $97.1M | $141.3M |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | $2.6M | $12.2M | $27.1M |
| Pre-Tax Income | $-110.0M | $-112.9M | $-187.8M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-110.0M | $-112.9M | $-187.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-107.5M | $-100.8M | $-160.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-107.5M | $-100.8M | $-160.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $220.5M | $296.6M | $434.9M |
| Cash & Equivalents | $52.4M | $249.1M | $149.3M |
| Marketable Securities | $161.2M | $39.1M | $275.5M |
| Accounts Receivable | $0 | — | — |
| Prepaid Expenses | $7.0M | $8.4M | $10.1M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $41.3M | $43.3M | $125.5M |
| PP&E (Net) | $22.3M | $20.1M | $19.5M |
| Operating Leases | $13.1M | $11.5M | $21.1M |
| LT Securities | $4.9M | $11.0M | $80.6M |
| Other LT Assets | $1.1M | $684.0K | $4.3M |
| Total Assets | $261.8M | $339.9M | $560.4M |
| Current Liabilities | $15.7M | $19.0M | $29.1M |
| Accounts Payable | $3.3M | $3.5M | $4.4M |
| Current Leases | $2.7M | $3.1M | $5.6M |
| Deferred Revenue | $884.0K | $273.0K | $257.0K |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $14.8M | $13.1M | $20.6M |
| LT Operating Leases | $13.5M | $11.5M | $19.0M |
| Other LT Liab | $233.0K | $617.0K | $603.0K |
| Total Liabilities | $30.5M | $32.1M | $49.8M |
| Shareholders' Equity | $231.3M | $307.8M | $510.6M |
| Retained Earnings | $-314.5M | $-415.3M | $-576.2M |
| AOCI | $-1.2M | $16.0K | $229.0K |
| Total L&E | $261.8M | $339.9M | $560.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-107.5M | $-100.8M | $-160.9M |
| Non-Cash Adjustments | $24.7M | $21.3M | $15.2M |
| Working Capital Changes | $-3.9M | $3.7M | $11.1M |
| Cash from Operations | $-86.7M | $-75.8M | $-134.6M |
| Capital Expenditures | $11.5M | $2.8M | $3.8M |
| Cash from Investing | $-17.1M | $115.7M | $-302.4M |
| Cash from Financing | $3.1M | $156.8M | $337.2M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-100.7M | $196.8M | $-99.8M |
| Beginning Cash | $153.0M | $52.4M | $249.1M |
| Ending Cash | $52.4M | $249.1M | $149.3M |
Frequently Asked Questions
How does 4D Molecular Therapeutics, Inc. make money?
The company's operations are currently concentrated in a single core segment: drug discovery and development. This segment encompasses the identification of novel targets, preclinical research, and clinical trial execution for its proprietary molecular programs aimed at treating cancer and immune disorders, with no distinct separate revenue streams or geographic divisions reported.
What are the main risks for FDMT?
The company faces substantial financial risk due to widening operating losses and an expanding deficit in retained earnings over recent years. Revenue has collapsed to zero in 2024 after a decline from 2023 levels, indicating potential commercialization delays or market access issues for existing assets. High burn rates coupled with limited revenue generation create dependency on successful equity financing rounds to fund ongoing clinical trials. Failure of any major clinical candidate could significantly impair the company's ability to continue operations without further capital infusion.
What is FDMT's competitive advantage?
The company leverages a proprietary small molecule discovery platform designed to identify unique therapeutic targets difficult for competitors to replicate. Its diverse pipeline of multiple clinical candidates provides potential exposure to various indications, reducing reliance on a single asset. Additionally, the firm maintains significant liquid cash reserves and marketable securities relative to its current liabilities, providing operational runway without immediate dilution pressure.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.